Amgen Inc. vs Genmab A/S: Annual Revenue Growth Compared

Amgen Inc. vs Genmab A/S: A Decade of Revenue Growth

In the competitive landscape of biotechnology, Amgen Inc. and Genmab A/S have showcased remarkable revenue trajectories over the past decade. From 2014 to 2023, Amgen's revenue surged by approximately 40%, reflecting its robust market strategies and innovative product pipeline. Meanwhile, Genmab A/S, a rising star in the biotech sector, experienced an astonishing growth of over 1800%, underscoring its rapid expansion and increasing market presence.

Key Insights

• Amgen Inc.: Starting with a revenue of $20 billion in 2014, Amgen reached nearly $28 billion by 2023, maintaining a steady growth rate.
• Genmab A/S: From a modest $850 million in 2014, Genmab's revenue skyrocketed to $16.5 billion in 2023, highlighting its aggressive growth strategy.

This comparison not only illustrates the dynamic nature of the biotech industry but also emphasizes the diverse growth strategies employed by these two giants.